PVLA
Palvella Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$157.24
+1.14%Aug 31, 2026, 11:30 UTC
Palvella Therapeutics completed the rolling submission of a New Drug Application to the FDA for QTORIN rapamycin for the treatment of microcystic lymphatic malformations.
Source:Aug 19, 2026, 03:11 UTC
Palvella Therapeutics raised $230 million through an equity offering to fund commercialization and pipeline expansion.
Source:Aug 6, 2026, 07:09 UTC
Palvella Therapeutics announced it is on track to complete its NDA submission for QTORIN rapamycin in microcystic lymphatic malformations during the second half of 2026, with potential FDA approval targeted for the first half of 2027.
Aug 4, 2026, 19:50 UTC
Palvella Therapeutics, Inc. held its Q2 2026 earnings call on August 4, 2026.
Source:Aug 4, 2026, 00:00 UTC
Palvella Therapeutics reported a net loss of $21.9 million for Q2 2026, with diluted EPS of -$1.52, compared to a net loss of $9.5 million in Q2 2025.
Jul 22, 2026, 07:47 UTC
Fifth Third Bancorp acquired a new stake in Palvella Therapeutics, Inc. by purchasing 19,947 shares valued at approximately $2.49 million.
Source:Jun 30, 2026, 00:00 UTC
Matthew Pauls was appointed as a Class I director of Palvella Therapeutics, Inc.
Jun 22, 2026, 11:48 UTC
The FDA granted rolling review for Palvella Therapeutics' New Drug Application for QTORIN rapamycin to treat microcystic lymphatic malformations.
Source:Jun 16, 2026, 00:00 UTC
Palvella Therapeutics, Inc. elected George M. Jenkins, Todd C. Davis, and John Doux as Class III Directors effective June 10, 2026.